WASHINGTON -- Lupus nephritis (LN) diagnosis could improve greatly if early results with a multimarker urine test are ...

There are multiple chapters near you. Select your preferred chapter.

Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it ...

Aurinia Pharmaceuticals (AUPH) has released an update.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top Wall ...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) commends the American College of Rheumatology (ACR) for their 2024 evidence-based guidelines for the screening, treatment, and ...

A range of medications are available to help treat lupus nephritis (LN), each offering a specific role in managing the ...

Fate Therapeutics (NASDAQ:FATE) stock rallied 37% Monday after the company reported that the first patient in the Phase 1 ...

The company said the patient, an African American-Asian woman diagnosed with lupus nephritis, received fludarabine-free ...

Aurinia Pharmaceuticals (AUPH) has released an update. Aurinia Pharmaceuticals has unveiled new data underscoring the importance of early ...

"Dosing the first lupus nephritis patient in our Phase 1 trial of ADI-001 marks an important step forward in our mission of ...

Kidney issues: Lupus can lead to kidney inflammation, or lupus nephritis, which is a serious complication that can affect kidney function. Respiratory and cardiovascular Issues: Difficulty breathing ...